Immunpathologia I.

Prof. Dr. Kiss András
Ph.D., D.Sc.
Semmelweis Egyetem
Budapest
II. Pathologiai Intézet

Őszi Szemeszter
2021 november



XX. századi technologiák

- Makroszkópia (indítás)
- Citologia
- Szövettan
- Citokémia
- Immunhiszto/
- citokémia
- Electronmikroszkópia
- Molekuláris biológia
- Molekuláris genetika
- XXI. század.








Immunhistochemistry

- Deparaffinization

- Antigen Retrieval / Microwave treatment (proteases, pressure cooker, etc,)

- Blocking Serum

- Primayr AB

- Secondary AB

- Avidin - Biotin - Complex
-Peroxidase Reaction / DAB /

- Backgorund staining / haematoxylin
(Nuclei are blue)



The Nobel Prize in Physiology or Medicine 1984

Niels K. Jerne

Georges J.F. Köhler

César Milstein

The Nobel Prize in Physiology or Medicine 1984 was awarded jointly to Niels K. Jerne, Georges J.F. Köhler and César Milstein *"for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies"*.

EGFR2/HER2 signal transduction (physiologic cond.)



Guidelines for Scoring **HercepTest™**

DAKO

Score to report	HER2 protein overexpression assessment	Staining pattern
0	Negative	No staining is observed, or membrane staining in less than 10% of the tumour cells.
1+	Negative	A faint/barely perceptible membrane staining is detected in more than 10% of the tumour cells. The cells are only stained in part of the membrane.
2+	Positive	A weak to moderate complete membrane staining is observed in more than 10% of the tumour cells.
3+	Positive	A strong complete membrane staining is observed in more than 10% of the tumour cells.



Score: 2+



Score: 3+



Score: 0



Score: 1+



Score: 2+



Score: 3+



Score: 0



Score: 1+



Score: 2+



Score: 3+

HercepTest™ Rare Staining Patterns and Artifacts



Example of heterogenous staining. Score: 3+



Example of cytoplasmic staining. Score: 0



Example of dot artifact. Score: 0



Example of edge artifact. Score: 1+



Example of retraction artifact. Score: 1+



Example of retraction artifact. Score: 1+



Example of thermal artifact. Score: 1+



Example of crushing artifact. Score: 1+

DAKO

Find out more about HercepTest™ by visiting DAKO on the worldwide web at www.dako.com or call your local DAKO distributor.

Australia
Tel. 2 9316 4633
Fax 2 9316 4773
Austria
Tel. 0800 0800 7153
Fax 0800 0800 7154
Canada
Tel. 905 858 8510
Fax 905 858 8801

Czech Republic
Tel. 05-41 42 37 10
Fax 05-41 42 37 11
Denmark
Tel. 44 85 95 00
Fax 44 85 95 95
France
Tel. 1 30 50 00 50
Fax 1 30 50 00 11

Germany
Tel. 040 69 69 470
Fax 040 69 52 741
Italy
Tel. 02 58 078 231
Fax 02 58 078 292
Japan
Tel. 075 211 3655
Fax 075 211 1755

The Netherlands
Tel. 020 42 11 100
Fax 020 42 11 101
Norway
Tel. 23 14 05 40
Fax 23 14 05 42
Poland
Tel. 058-661 1879
Fax 058-661 3390

Spain
Tel. 93 499 05 06
Fax 93 499 02 08
Sweden
Tel. 08 556 20 600
Fax 08 556 20 619
Switzerland
Tel. 041 760 11 66
Fax 041 760 11 77

United Kingdom
Tel. (0)1 353 66 99 11
Fax (0)1 353 66 89 89
United States of America
Tel. 805 566 6655
Fax 805 566 6688

Photos by James Thompson, MD, PhD, Director of Pathology, Biopharmaceutical Services, Impath Laboratories, Frolan Espinoza, MD, Molecular Tissue Pathology, Quest Diagnostics/Nichols Institute and DAKO.

Betegség Mentes Túlélés

Romond H et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer NEJM 2005; 353:1673-1684



HER2 expresszió emlőrákban



3+ CB11



MOLEKULÁRIS PATOLÓGOIA

HER2 - Emlőrák



Chromosome 17



Gyulladások klasszifikációja időbeni lefolyás alapján

HYPERAKUT (Perakut)

AKUT

SUBAKUT

KRÓNIKUS

PRIMER KRÓNIKUS (pl. PCP)

SZEKUNDER KRÓNIKUS


SZEPTIKUS LÉP

Neutrophil Granulocyza
(enzimeket szekretálnak,
elpusztítják a baktériumokat)

Eosinophil Gr.
(MBP, ECP) paraziták, férgek ellen
Makrofágok (a gyulladásos folyamatot szervezik: citokinek,
sejtek aktiválása, összekötik a veleszületett és szerzett immunitást)
Endothel sejtek (exsudatio, leukociták mozgása)
Fibroblastok (regeneráció)
Thrombocyták: (bFGF, TGFb, PDGF)
Lymphocyták

Marginatio
Gördulés
Adhésió - kitapadás
Transmigráció (Diapedesis)
Chemotaxis



Leukocyták mozgása

Az immunrendszer feladata

a szervezet integritásának megőrzése

az egyedi/saját struktúrák védelme

védelem a kórokozók ellen

védelem a malignus tumorok ellen

Immunrendszer a kórokozók elleni védelemre



- Lymphocyta
- Antitest
- Makrophag
- Granulocyta
- NK sejtek
- hízósejtek
- dendritikus sejtek
- Komplement
- Lyzozym
- C-reaktiv protein

Allergiás gyulladás nem pathogén károsodásra



A gyulladás sejtes elemei

	Basophils and Mast Cells	*Neutrophils*	*Eosinophils*	*Monocytes and Macrophages*	*Lymphocytes and Plasma Cells*	*Dendritic Cells*
						
% of WBCs in blood	*Rare*	*50–70%*	*1–3%*	*1–6%*	*20–35%*	*NA*
Subtypes and nicknames		Called "polys" or "segs" Immature forms called "bands" or "stabs"		Called the mononuclear phagocyte system	B lymphocytes, Plasma cells T lymphocytes Cytotoxic T cells Helper T cells Natural killer cells Memory cells	Also called Langerhans cells, veiled cells
Primary function(s)	Release chemicals that mediate inflammation and allergic responses	Ingest and destroy invaders	Destroy invaders, particularly antibody-coated parasites	Ingest and destroy invaders Antigen presentation	Specific responses to invaders, including antibody production	Recognize pathogens and activate other immune cells by antigen presentation in lymph nodes
Classifications		*Phagocytes*				
		Granulocytes				
			Cytotoxic cells		*Cytotoxic cells (some types)*	
				Antigen-presenting cells		

A nem specifikus immunrednszer sejtjei

makrofágok, dendritikus sejtek, granulociták, hízósejtek, NK sejtek

Phagocytosis
of a bacterium covered by IgG



Phagocytosis makrofágokban és neutrofil granulocitákban

Zerfall der neutrophilen Granulozyten setzt Elastase frei – Konzentration im Serum gibt diagnostische Hinweise auf den Schweregrad einer Entzündung.



NADPH Oxidase Mutation – verursacht die Krankheit chronische Granulomatose (charakterisiert durch chronischen, persistänten bakteriellen Infektionen).



MASP= MBL-associated serine protease

Komplement aktiváció: klasszikus útvonal

1E.



1F.



MAC-membrane-attack complex

Quelle: Kuby Immunology, W.H. Freeman and Company

Komplement aktiváció 2.: alternatív útvonal (antitest független)



Initiiert durch körperfremde bakterielle Zelloberflächemoleküle!

Sialinsäure auf eukaryotischen Zellen inhibieren C3b!!!

Quelle: Kuby Immunology, W.H. Freeman and Company


Thymus
normál immun funkció
Autoimmunitás
Relatív erősség
10
20
30
40
50
60
70
80
kor (évek)

Candidiasis - soor mycosis

Száj nyálkahártya

Bőr hajlatok

glans penis

Női genitáliák

Inkább idős vagy obes betegek, nők

Predispositio:

- diabetes
- nedves felületek
- B vitamin hiány
- terhesség
- atrophia

SEJTekre ható MEDIÁTOROK

HISTAMIN - allergiás (hypersensitivitás) GYULLADÁS

SEROTONIN:

PROSTAGLANDIN:

LYMPHOKIN:

LEUKOTRIÉN:

TROMBOCYTA Aktiváló Faktor (PAF):

INTERFERON: α: from LEUKOCYTA,
β: from FIBROBLASTOK
γ: from ACTIVATED T-LYMPHOCYTÁK

Severe COVID-19



Bhatraju PK et al NEJM 2020



Merad M et al, Nat Rev Immunol. 2020

Inflammation is caused by immune dysregulation in severe COVID-19

- Lymphocytopenia is characterised by low CD4+ with predominance of Th2 lymphocytes, low CD19+ lymphocytes, and low NK cells
- Monocytes display a reduced expression of both CD14 and HLA-DR
- An inverse correlation exists between HLA-DR molecules on CD14-monocytes and serum levels of IL-6

Giamarellos-Bourboulis E et al. Cell 2020
Lombardi A et al doi: https://doi.org/10.1101/2020.05.01.20087080


Proinflammatory cytokines and procoagulant factors
Venule
Hyaline thrombi
Arteriole
Macrophages and lymphocytes infiltrating vessel wall
Neutrophils
Macrophages
Clot formation
Vascular rupture and haemorrhage
Proinflammatory mediators
Cytokines and procoagulant enter capillary network
McGonagle D Lancet Rheumatol 2020
isth 2020

<u>Immuntolerancia</u>: elnyomott vagy hiányzó reaktivitás
BIZONYOS ANTIGÉNEKRE, míg másokra megtartott válaszreakció
Embryonalis fázisban – de nem érett immunrendszerben – antigének, mint saját struktúraként elismerve és ez az állapot fennmarad.

Megkülönböztetve: »saját « és „ idegen”/ » nem saját «
Ez elveszhet később „tolerogének ” hatására, és így autoaggresszív betegségek keletkezéséhez vezethet.
Veleszületett: saját , testazonos antigénekre (Autoantigének)

Szerzett: reciprok immuntolerancia ikrekben
(éranasztomózisok placentában)

<u>Immun deficiencia szindrómák</u>: defekt, sérült immunreakció
Általános elégtelensége a szervezetnek, hogy egy immunreakcióval válaszoljon egy egyébként elégséges antigén stimulusra
(a specifikus tolerancia ellentéte)

Impetigo contagiosa

Primeren gennyes bőrfertőzés.
Leginkább immundeficiens gyerekekben

Koszos/ non / higiénikus körülmények , karmolások elősegítik

Komplikáció.: Impetigo-Nephritis

Ekthyma
Kifekélyesedett pyodermia

Kompl.: Lymphangitis
Lymphadenitis,
Phlebitis

ß-hämolyth. streptococcus

Csökkent bőrvédekezés

Lokális keringési zavar

Tumorimmunitás

A malignus daganatok gyakrabban fordulnak elő legyengült immunitással rendelkező vagy immundeficiens betegeknél.

Okai: kor, chemoterápia, irradiáció, immundefektusok

A tumor sejtek az immunrendszert elkerülő mechanizmusokat fejlesztenek ki:

(neo) antigén negatív variánsok (subklónok)

a hisztokompatibilitás antigének elveszett vagy csökkent expressziója
$\Rightarrow$ a tumorsejtek elkerülik a cytotoxikus T-sejteket

hiányzó peptidantigén-ko-stimuláció

immunsuppresszió, pl. TGF-ß termelődése és szekréciója tumorokban

A cytotoxikus T-sejtek apoptosisa a FAS-Ligandok expresszója által: pl. melanoma, hepatocellular carcinoma

Az immun védelem sejtjei: lymphocyták, natural killer sejtek,

makrophágok

Onkológiai immunterápia

Specifikus, aktivált T-sejtek: lymphokin aktivált Killer sejtek (NK)

a beteg véréből izolálva

sejtkultúrában stimulálva

visszaadva a betegnek

Blokkoló antitestek terápiás alkalmazása:

epidermal growth factor receptor: EGFR ellen

C-Kit receptor fehérje blokkolás (Thyrosin kinase function) CML, GIST

Overexpresszált receptorok blokkolása antitestel: Herceptin (Erbb2)

Tumorok antiegenitásának növelése apathogenén vírus infekcióval

Immunprofilaxis speciális esetekben: – pl. HBV-vakcina: primer hepatocellular carcinoma prevenció

The Founders of Modern Immunology and Immuno-Therapy

Robert Koch

Paul Ehrlich

William Coley

Emil v. Behring

Louis Pasteur

Rudolf Virchow

Ilja Iljitsch Metschnikow

Prize announcement



Announcement of the 2018 Nobel Prize in Physiology or Medicine by Professor Thomas Perlmann, Secretary of the Nobel Committee for Physiology or Medicine, on 1 October 2018.

"We can cure cancer with it"

Klas Kärre, member of the Nobel Committee, on the life-changing possibilities of this year's Nobel Prize awarded discovery. Professor Kärre, member of the Nobel Committee for Physiology or Medicine, was interviewed by freelance journalist Lotta Fredholm following the announcement of the 2018 Nobel Prize in Physiology or Medicine.



Figure: Upper left: *Activation of T cells requires that the T-cell receptor binds to structures on other immune cells recognized as ”non-self”. A protein functioning as a T-cell accelerator is also required for T cell activation. CTLA- 4 functions as a brake on T cells that inhibits the function of the accelerator.* ***Lower left:*** *Antibodies (green) against CTLA-4 block the function of the brake leading to activation of T cells and attack on cancer cells.****Upper right:*** *PD-1 is another T-cell brake that inhibits T-cell activation.* ***Lower right:*** *Antibodies against PD-1 inhibit the function of the brake leading to activation of T cells and highly efficient attack on cancer cells.*

What Have We Learned About the Role of the Immune System in Oncology?



HIV = human immunodeficiency virus; LAK = lymphokine-activated killer; IL-2 = interleukin-2; NKT = natural killer T.

1. Coley WB. *Am J Med Sci.* 1893;105:487–511. **2.** Ichim CV. *J Transl Med.* 20058;3:8. **3.** Levine AM et al. *Curr Probl Cancer.* 1987;11:209–55. **4.** Rosenberg SA et al. *N Engl J Med.* 1985;313:1485–1492. **5.** van der Bruggen P et al. *Science.* 1991;254:1643–1647. **6.** Tivol EA. et al. *Immunity.* 1995;3:541–547. **7.** Vesely MD et al. *Annu Rev Immunol.* 2011;29:235–271. **8.** Shankaran V. et al. *Nature.* 2001;410:1107–1111. **9.** Drake CG *et al. Nat. Rev. Clin. Oncol.* 2014;11: 24–37.

The Immune System



⇒ **fast response and low specificity**

- **Antibodies**
- **Cytokines**
- **Ag receptors (10^9 / individual)**

⇒ **specificity, diversity, and memory**

Dranoff, 2004

"Immune Checkpoint-Blockade In Cancer" Beginning of a New Era!



Immuno Oncology: A Graphical Abstract



T-Cell Activity Is Regulated By Immune Checkpoints to Limit Autoimmunity[1]



CTLA-4 = cytotoxic T-lymphocyte antigen 4; PD-1 = programmed cell death protein 1; LAG-3 = lymphocyte activation gene 3; TIM-3 = T-cell immunoglobulin and mucin protein 3.

1. Pardoll DM. *Nat Rev Cancer*. 2012;12:252–264.

3. Exploiting the PD-1 Immune Checkpoint Pathway[1]



- PD-1 is upregulated on activated T cells during the effector phase of the immune response
- PD-L1 and PD-L2 engage the PD-1 receptor on T cells to downregulate T-cell activity in the effector phase

Reprinted by permission from Macmillan Publishers Ltd: *Nat Rev Cancer,*[1] copyright 2012.

PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1; PD-L2 = programmed cell death ligand 2.

1. Pardoll DM. *Nat Rev Cancer*. 2012;12:252–264.

The Cancer-Immunity Cycle
- Immunoediting: 1.) Elimination -



Chen and Mellman Immunity, 2013, 39:1-10

The Cancer-Immunity Cycle
- Immunoediting: 2.) Equilibrium -



Tumour equilibrium



Immune Checkpoint Inhibitors



Immune Checkpoint Inhibitors



Chen and Mellman Immunity, 2013, 39:1-10

Three Categories of Response to Anti-PD-1/PD-L1



Immunogenic vs. Non-immunogenic Tumors



Biomarker Analysis: Tumor-Infiltrating Lymphocytes



Schmidt P. et al. AACR 2017 Phase Ia Atezolizumab in TNBC

Biomarker Analysis: Tumor-Infiltrating Lymphocytes



	≤ 10% TILs (n = 53)	> 10% TILs (n = 56)
mOS (95% CI)	6.6 mo (4.9, 10.2)	12.6 mo (10.5, NA)

- Higher ORR and longer OS were seen with higher baseline TIL (CD8) infiltration

Schmid P, et al. AACR 2017 Phase Ia Atezolizumab in TNBC

Future Directions in Immuno-Oncology



3. Priming and activation

16 7

4. Trafficking of T cells to tumors

14 1

5. Effector T cell Infiltration into tumors

11 12 2

6. T cell recognition of cancer cells

29 23 4

7. T cell killing of cancer cells

26 12

2. Cancer antigen presentation

1. Release/Exposure of cancer antigens

Chemotherapy

The bubble contains # of trials in -
- Phase I
- Phase II
- Phase III

Note - Trials may test more than 1 agent

Chen and Mellman Immunity, 2013, 39:1-10

Summary and Future Directions



Chemotherapy

Targeted therapy

Immune checkpoint therapy

⇒ long lasting responses
⇒ applicable in various cancer types

Combination therapy

⇒ increase in response rate
⇒ increase in efficiency

I. Típusú túlérzékenységi reakció

első antigén expozíció

(hízósejt, bazofil leukocita FcεR)

DEGRANULÁCIÓ

LTB4	histamin	hisztamin
Kemotaktikus faktorok	PAF	LTD4
Cytokinek	PGE_2	PE
	LTD4E4	PAF
Kemotaxis/exsudatio	vasodilatatio érpermeabilitás nő	simaizom-spazmus

ACTIVATION OF MAST CELLS IN TYPE I HYPERSENSITIVITY *REACTION*



Antigen
IgE
IgE Fc receptor
Signals for degranulation
Signals for activation of phospholipase A_2
Signals for cytokine gene activation
Nucleus
Membrane phospholipids
Granule contents
- Histamine
- Proteases
- Chemotactic factors (ECF, NCF)

Secreted cytokines
Arachidonic acid
PAF
Leukotrienes B_4, C_4, D_4
Prostaglandin D_2
Primary mediators
Secondary mediators

PATOGENESIS OF TYPE I HYPERSENSITIVITY REACTION



Allergia

- Lokális: rhinitis, asthma, conjunctivitis
  - bőr: urticaria, ekzema, angioneurotikus oedema,
- Szisztémás: anaphylaxias shock
- (adrenalin: simaizom relax, nincs vasospazmus)

Generalizált anaphylacticus reakció

https://www.youtube.com/watch?v=j8wwNpkpEN0

II. Típusú túlérzékenységi reakció

A. Komplement-függő reakció

Célsejt antitest-kötése

C5-9 C1423

Komplement-függő sejtpusztulás

B. Antitest-függő celluláris citotoxicitás

Célsejt antitest-kötése (Fc expozíció)

FcR+ effektorsejt-kapcsolat (NK sejt, makrofág)

Célsejt pusztulás

C. Receptor-ellenes antitestek által mediált folyamatok

Anti-receptor-antitest termelődés



Myastenia gravis

Basedov-Graves kór

II-es típusú hypersensitivitási reakció (cytotoxicus)



Hydrops foetus universalis

Rh incompatibilitás

(Parvovirus B 19 infectio)

Tüdő vérzés. Goodpasture syndrome

III. Típusú túlérzékenységi reakció

2. antigén-expozíció — antigén/antitest komplex keletkezés (keringés)

immunkomplex lerakódás
(vese, bár, savós hártyák, érfal)

vazodilatáció
oedema

neutrofil migráció
degranuláció

thrombocyta aggregáció
microthrombus
ischemia

szövet-nekrózis

patomechanizmus

- Acut:
- AG/AT komplex (Se), lerakódás, gyulladás…..C3b (fagocitózis)C5b,6/7: kemotaxis, (gyulladás), C5-9membránattak komplex…sejtpusztulás

- Fibronoid érfal necrosis, vasculitis (neu)



Az alapvető szövettani jelenség a:

***necrotisáló* vasculitis**



II. patomechanizmus

- Chronicus: perzisztens antigén
- Okok: „autoimmun betegség”
- kigyóméreg elleni szérumok, egér anti-humán T sejt szérum, bakteriális streptokináz, iv. penicillin





IV. Típusú túlérzékenységi reakció

A. Késői típusú hypersensitivitás

2. antigén-expozíció — dendritikus sejt – T sejt kapcsolódás (IL-2, TNFα, IFNγ)

lymphocyta accumulatio — fibroblast-proliferáció érújdonképződés — makrofág-aktiválódás

B. T-sejt mediált celluláris cytotoxicitás

Idegen antigén-hordozó célsejt (vírus-fertőzött sejt, allograft)



Granuloma képződés



TBC-tüdő

Transplantációs patológia

- Host-versus graft: szervtranspl
- Graft-versus host (csontvelő trpl)

A transplantatum kilökődése



A TRANSPLANTÁTUM KILÖKŐDÉSE (REJECTIO, VESE)

HYPERACUT

perceken belül

(a recipiensben performált AT-ek

ACUT

hetek-hónapok hirtelen veseelégtelenség

therápia!!!

therápia resistens!!!

CHRONICUS

hónapok-évek

azotaemia

oliguria

hypertonia

ARTHUS-REACTIO

fibrinoid necrosis az érfalban

./ Cellularis

interstit. nephr. **II.-IV. h.r.**

(mononucl. oedema)

a tubularis epith. focalis necrosisa

Cyclosporin A toxicitás!!!

./ Vascularis

necrotisalo vasculitis

glomerulus necrosis

III. h.r. **a cortex a. thrombosisa**

subacut vasculitis (intima prolifer.)

érelváltozások

intimafibrosis **sec. ishaemia** →

↓

tubularis atrophia

interstit. fibrosis- vese zsugorodás

Acut rejectio



Chronicus rejectio



Örökletes immunhiányos állapotok, humorális

- X-kötött hypogammaglobulinaemia (Bruton), BTK hiány, propreB van csak,

Enterális fertőzések (vírus, Giardia, Mycopl)

- Átmeneti hypogammaglobulinaemia (T helper)
- Hyper-IgM (CD40L hiány)

Izotípus váltás nincsen, ok CD4+T sejt funkciózavar (IgA, IgE IgG hiány), kóros IgM, nincsen csíracentrum…..

- Variábilis hypogammaglobulinaemia (B és T zavar)
- **Szelektív IgA hiány (leggyakoribb)**

C4A-del, CD8+T zavar, izotípusváltási zavar: bél, bőr fertőzések…

- 5'-nukleotidáz hiány: perB van csak……

Örökletes immunhiányos állapotok, celluláris

- Di-George (thymus aplasia, 22q11del)

Szívfejlődési rendell+ hypoparathyr), fejlődési rendellenesség (3/4 garatív), preT van csak

- Chr mucocutan candidiasis

Örökletes immunhiányos állapotok, kevert

- SCID: CYKR g-lánc mutáció

Főleg T probléma (X kötött, fiúkban)

- Adenozin deamináz hiány (au-rec)

dATP toxikus a T sejtekre….DNS lézió!!!

- Purinnukleotid foszforiláz-hiány (dGTP toxikus, T, DNS!!!)
- Wiskott-Adrich szindroma (X-kötött, fiúk)

Xp1123 gén hiány

Fertőzések, thrombocytopenia, ekzema

- Ataxia teleangiectasia .

Thymus hyopolasia, nycs atrophia, T+IgG/IgA hiány (DNS hibajavító gén)

- Retikuláris dysgenesis (myel, ly őssejt zavar)
- Csupasz ly szindroma (HLA-II hiány), CD4T probléma: CIITA, RFX transzkripciós faktorok zavara
- Alacsony HLA-I expresszió (peptidtranszporter zavar) CD8 zavar…..

Varicella

Varicella-Zoster-Virus

(air born-, rarely contact infection), very infectious !

Varicella exanthems an the body

Varoicella and acute lymphoid leukemia - ALL



necrotizing pneumonia in varicella generalisata





Varicella

Herpes zoster

thorakaler Herpes zoster (Zoster intercostalis)

herpes zooster ophtalmicus

Herpes simplex on the lips

HSV-1 Infection

Cold sore



HSV-1 Infektion in Leukamie-Patient

HSV-1 Infektion



Szerzett immunhiányos állapot, AIDS

- HIV1/2 fertőzés okozta szelektív CD4 hiány
- Szex, vér, transzplacentáris behatolás
- Célsejt: CD4+T (gp120HIV), citotoxikus
- Célsejt: makrofág (nem toxikus, rezervoár)….endotél?
- Szolubilis gp120+CD4T/anti-gp120 ADCC







CD4/CD8 arány: 2-4/1

HIV fertőzéskor: lecsökken/megfordul


gp41
p17 matrix
gp120
p24 capsid
Lipid bilayer
Integrase
Protease
RNA
Reverse transcriptase

HIV-1


HIV-Neuinfektionen
in Deutschland, geschätzt
7000
6000
5000
4000
3000
2000
1000
Quelle: Robert-Koch-Institut
1979 81 83 85 87 89 91 93 95 97 99 01 03 05

AIDS-Tote in Kenia - apokalyptischer Zustand

in Afrika verheert das Virus Völker und Volkswirtschaften

structural components of human immunodeficiency virus, the key antigenic components are diagrammed here





the phylogeny of human immunodeficiency virus (HIV) subtypes and simian immunodeficiency virus (SIV)

AIDS lefolyása

- LND: follikuláris hyperplasia (B), HIV+T zóna, CD4->5OO/ul,, p24+
- Follikuláris involutio (dendritikus sejtes zavar), latens AIDS:CD4T csökken, lappang a vírus
- Opportunista fertőzések: krízis, viraemia, CD4T<2OO/ul
- Lép, thymus sorvadás, dementia (microglia)
- Kaposi sarcoma (HHV8-angiosarcoma), B-NHL (agyi), méhnyakrák-HPV

Opportunista fertőzések AIDS-ben

Helminthiasis		
	Strongyloides	gastroenteritis, sepsis
Protozoonok		
	Pneumocystis carinii	pneumonia
	Toxoplasma gondii	encephalitis, disseminalt forma
	Cryptosporidium	enteritis
	Isospora belli	enteritis
Gombák		
	Candida albicans	oesophagitis
	Cryptococcus	meningitis
	Histoplasmosis	disseminalt forma
	Coccidiomycosis	disseminalt forma
Baktériumok		
	Mycobacterium avium	disseminalt forma
	Mycobacterium kansasii	
	Mycobacterium bovis	extrapulmonáris tuberculosis
	Salmonella	septicaemia
	Bacterialis pneumonia	recidivans
Vírusok		
	Herpes simplex	mucocutan
		Bronchialis
		Oesophagealis
	CMV	disseminalt
Prion	vCJ betegség	leucoencephalopathia

Inkubációs idő 7-8 év a T4 helper sejtek pusztulásáig

Vér: Lymphopenia T4 <<<T8

Tüdő: Pneumozystis-Pneumonia
Zytomegalovírus-Pneumonia
lymphoid intersitiális Pneumonia
desquamativ interstitiális Pneumonia
diffus alveolaris károsodás syndroma
lymphoreticuláris hyperplasia

Nyirokcsomó: Lymphadenopathia
non-Hodgkin Lymphoma

Bőr: Kaposi-Sarkoma

Bél: B-Zell-Lymphoma
Kaposi-Sarkoma a AIDS-betegek 25 %-ában

Máj: Portalis terület infiltratiója

Agy: multifokalis Leukoenzephalopathia

opportunista infekciók
Pneumocystis carini
Candida albicans
Toxoplasma gondii
Mycobacterium tuberculosis
Herpes és Zytomegalo Virusok

Opportunistische Infektionen in AIDS

Helminthiase		
	Strongyloides	Gastroenteritis, Sepsis
Protozoa		
	Pneumocystis carinii	Pneumonie
	Toxoplasma gondii	Enzephalitis, disseminnierte Form
	Cryptosporidium	Enteritis
	Isospora belli	Enteritis
Pilze		
	Candida albicans	Ösophagitis
	Cryptococcus	Meningitis
	Histoplasmosis	disseminnierte Form
	Coccidiomycosis	disseminnierte Form
Bakterien		
	Mycobacterium avium	disseminnierte Form
	Mycobacterium kansasii	
	Mycobacterium bovis	extrapulmonare Tuberkulose
	Salmonella	Septicaemie
	Bakterille Pneumonie	Rezidivans
Viren		
	Herpes simplex	mucocutan
		bronchial
		ösophageal
	CMV	dissemiiniert
Prion	vCJ betegség	Leukoencephalopathie

CMV infection has no characteristic gross appearance in any organ - cecal ulceration



CMV-colitis in AIDS patient



CMV-vasculitis in AIDS patient



CMV often produce a pneumonia – CMV inclusions in lung



the appearance of Pneumocystis carinii caused extensive pneumonia






A
B
C
D

Pneumocystis carinii pneumonia

may produce cavitary change

in rare cases



the appearance of Pneumocystis carinii in lung with exudate in nearly every alveolus



Pneumocystis carinii in lung is demonstrated by the appearance of brown to black cysts in the alveolar exudate - Gömöri stain



faint bluish dot-like intracystic bodies of Pneumocystis carinii in lung in this cytologic preparation from a BAL - Giemsa stain



immunoperoxidase stain with antibody to Pneumocystis carinii: the brown-red reaction produce is seen highlighting the exudates

dissemination to extrapulmonary sites: Pneumocystis carinii tends to produce foci with prominent calcification

disseminated of Pneumocystis carinii has led to splenomegaly, and the masses of exudate produce the lucent areas in spleen - CT scan



Pneumocystis carinii can produce large areas of the foamy pink exudate that can calcify in the lung







CANDIDIASIS az

OESOPHAGUSBAN



CANDIDIASIS OESOPHAGUSBAN (PAS reakció)